(Total Views: 578)
Posted On: 05/19/2024 7:00:25 PM
Post# of 153941
thanks ohm,
is the reason it wouldn't be considered a drug conjugate because keytruda is a once/month IV infusion while leronlimab is a once/week sub-q injection?
why then is merck trialing keytruda by the 100's with drugs it is not compatible with to be conjugated?
is all that would be required to make this conjugatable is to give leronlimab once/monthly IV? after all, we did give leronlimab IV in Brazil I believe. What if the trial was set up using leronlimab once monthly IV to coincide with the keytruda dosing schedule, would it then be considered a conjugate, and could that be patented if the trial was statistically significant?
is the reason it wouldn't be considered a drug conjugate because keytruda is a once/month IV infusion while leronlimab is a once/week sub-q injection?
why then is merck trialing keytruda by the 100's with drugs it is not compatible with to be conjugated?
is all that would be required to make this conjugatable is to give leronlimab once/monthly IV? after all, we did give leronlimab IV in Brazil I believe. What if the trial was set up using leronlimab once monthly IV to coincide with the keytruda dosing schedule, would it then be considered a conjugate, and could that be patented if the trial was statistically significant?
(5)
(0)
